0039 GMT - Aurizon's interim dividend of A$0.125/share--versus consensus of A$0.098--is the main surprise in a generally positive result, according to Citi analyst Samuel Seow. The dividend "may signal a potential step change in capital management going forward," says Seow. Group Ebitda of A$891 million is 3% ahead of market expectations, he says. "Overall a beat, although it appears driven by coal which is expected to reverse in 2H," Seow says. Citi keeps a neutral rating and A$3.45 target on Aurizon. The stock is up 5.9% at A$3.80. ([email protected]; @RhiannonHoyle)

0038 GMT - Westpac's costs are seen by UBS analyst John Storey as the standout of the Australian lender's December-quarter result. Costs were down 5% on the average of the prior two quarters, which helps support Storey's upgraded EPS forecasts. He tells clients in a note that Westpac's overall franchise is showing strong momentum, with lending-asset growth of about 10% and annualized deposit growth of 6.7%. He sees improvement across the banking sector, supported by stable asset quality and credit growth, particularly in wholesale lending. UBS keeps a neutral rating and A$40.00 target price on the stock, which is down 0.8% at A$40.19. ([email protected])

0012 GMT - Westpac's bears at Macquarie say the Australian lender continues to underperform relative to its peers. The bank beat consensus expectations for the December quarter, but Macquarie's analysts reckon that timing issues partly explain why costs were lower than forecast. They tell clients in a note that wage increases came in during January, while Westpac also benefited from seasonally low investment spend. The analysts point out that underlying margins were softer than those at Australia's other major banks, although they concede that volume growth was solid. Macquarie keeps an underperform rating and A$35.00 target price on the stock, which is down 1.0% at A$40.13. ([email protected])

0006 GMT - Westpac's stronger-than-expected first-quarter profit does nothing to shift the bearish view of the stock at Morgan Stanley. Investor expectations, combined with limited scope for a positive surprise on margins, costs and capital management, keep MS analyst Richard E. Wiles underweight on the stock. He tells clients in a note that the share-price performance heading into the profit announcement suggested that investors were expecting a better result. A derating of the stock's earnings multiple looks possible given Westpac aims to win back market share and has a materially lower capital buffer. MS lifts its target price 3.5% to A$35.70. Shares are down 0.9% at A$40.17. ([email protected])

2339 GMT - Australian Clinical Labs' strong cost control in 1H was overshadowed by an earnings downgrade and the departure of CEO Melinda McGrath, says Ord Minnett. Shares of ACL drop 9.5% to A$2.19 in early trading. ACL reported 1H underlying Ebit of A$28.0 million, up some 7% on Ord Minnett's estimate. Underlying net profit was a 9% beat to the bank's forecasts. Still, ACL expects FY 2026 Ebit of A$64 million-A$67 million, representing a 6% downgrade at the midpoint. "Overall, a better-than-expected 1H26 result (on strong cost control) but we expect the focus to be on the downgraded FY 2026 guidance, a weaker set-up for FY 2027 and the CEO exit," analyst Tom Godfrey says. "ACL's share price has declined 9% over the last month into the result and we expect further weakness today." ([email protected]; @dwinningWSJ)

2335 GMT - Cochlear's bull at Canaccord Genuity sees nothing in its operations to justify the size of the selloff that followed the hearing-tech provider's 1H profit miss. Analyst Shane Storey keeps a buy rating on the Australia-listed stock, telling clients in a note that a 19% share-price fall seems extreme on a 5% net profit miss. Shareholder emotion and frustration are the only reasons he can give to explain the drop. Storey observes that the selloff took the company's earnings multiple to a 10-year low and sees this as a buying opportunity that echoes one sparked in 2011 by a product recall. Canaccord Genuity cuts its target price 11% to A$295.00. Shares are up 2.7% at A$204.68. ([email protected])

2334 GMT - Ord Minnett is upbeat about Genesis Minerals' planned takeover of Magnetic Resources. Genesis today said it has agreed to a deal that values Magnetic's equity at roughly A$639 million. Under the offer, Magnetic shareholders will get A$1.40 in cash and 0.0873 share in Genesis for each share that they own."At first glance, this looks like attractive bolt-on when considering the price paid," analyst Paul Kaner said. Ord Minnett also likes the potential for savings from combining operations. "Furthermore, it justifies a Laverton mill expansion to 4.5 million-5 million tons per annum to drive production growth to +500,000 oz per annum," Ord Minnett adds. "As such, we'd expect the market to look favorably upon this deal over time." ([email protected]; @dwinningWSJ)

2334 GMT - JB Hi-Fi's shares rise after what Jefferies considers to be a solid 1H result in an uncertain retail environment. Analyst Michael Simotas says JB Hi-Fi's sales momentum continued through 2Q. That was particularly pleasing for The Good Guys business, given its sales measured up against a strong period a year earlier. "Gross margin was robust, suggesting strong supplier support," Jefferies says. While trading in January was slightly slower, JB Hi-Fi had a relatively high bar to clear because of its performance a year ago. "A good outcome amongst other weaker retailer updates and stock should perform well given recent share price weakness," says Jefferies. It retains a hold call on JB Hi-Fi. Shares are up 2.3% at A$78.43. ([email protected]; @dwinningWSJ)

2333 GMT - Ansell's 1H earnings beat should offset any market concerns over softer-than-expected revenue, RBC Capital Markets analyst Craig Wong-Pan says. The personal protective equipment manufacturer's December-half sales fell short of consensus, with Wong-Pan pointing to its healthcare unit as the largest underperformer. However, he tells clients in a note that efficiency and productivity initiatives supported beats relative to consensus on both Ebit and EPS. This should be well received by the market, he adds. RBC has a last-published outperform rating and A$41.00 target price on the stock, which is flat at A$31.28. ([email protected])

2332 GMT - The blemish on GPT's annual result was its dividend outlook, signals Jefferies. GPT's result for last year was in line and guidance for funds from operations of 35.4 Australian cents per security in 2026 also met expectations. However, analyst Andrew Dodds says GPT's forecast dividend of 24.5 cents/security in 2026 was 3% below his own projection of 25.3 cents. The miss reflects a 9% rise in maintenance and leasing capex. "We wouldn't expect material consensus FFO/security revisions following today's results," Jefferies says. "However consensus distribution growth going forward will likely be wound back." GPT is down 0.6% at A$5.00 in early trading, underperforming the benchmark S&P/ASX 200 index, which is up 0.3%.([email protected]; @dwinningWSJ)

(END) Dow Jones Newswires